 |
Satellite Symposium
Sheraton Grand Chicago
Chicago Ballroom VI
Chicago, Illinois
|
|
Faculty
 |
 |
 |
Robert Sidonio, Jr., MD
Associate Director
Hemostasis and Thrombosis
Emory University
Atlanta, Georgia |
Miguel A. Escobar, MD
Professor of Medicine and Pediatrics
Director, Clinical Research Center
McGovern Medical School
The University of Texas Health Science Center
Houston, Texas |
Angela C. Weyand, MD
Clinical Assistant Professor
Pediatrics - Hematology/Oncology
University of Michigan, Ann Arbor
Ann Arbor, Michigan |
Agenda
| 10 minutes |
The Current Standard of Care in von Willebrand Disease; Meeting Today’s Challenges |
| 15 minutes |
VWD and Prophylaxis: Applying Guidelines to Best Practice |
| 10 minutes |
Therapeutic Strategies in VWD: A Closer Look at the Use of Prophylaxis Treatment |
| 20 minutes |
Faculty Panel Case Discussion: Establishing a Plan of Care |
| 5 minutes |
Conclusion, Question & Answer Session |
Program Overview
von Willebrand Disease (VWD) is the most common inherited bleeding disorder in the United States. This live satellite symposium will address the importance of long-term prophylaxis in VWD, guideline recommendations for long-term prophylaxis, and emerging data on novel agents for prophylaxis in this disease. This program will conclude with case discussions designed to improve the awareness concerning symptoms of VWD and diagnostic assessments in order to better manage and treat the patients in your practice.
Target Audience
This program is intended for hematologists, primary care physicians, pediatricians, obstetricians, gynecologists, physician assistants, nurses and other healthcare professionals who provide care for patients with von Willebrand Disease (VWD).
Learning Objectives
Upon completion of this educational activity, participants should be able to:
- Outline recent guidelines concerning the use of short- and long-term prophylaxis in patients with von Willebrand Disease (VWD)
- Identify patient and disease characteristics that suggests a patient with von Willebrand Disease will benefit from long-term prophylaxis
- Summarize the safety and efficacy data from recent and ongoing trials investigating novel prophylaxis agents for VWD
- Outline factors that must be considered when identifying therapeutic strategies, doses, and regimens for prophylaxis in patients with VWD
|
|
|
Accreditation
 |
CME Credit
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
MediCom Worldwide, Inc. designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. |
|
Nursing Credit
MediCom Worldwide, Inc. is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 22-005-154
|
Disclosure
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an accredited continuing education activity to disclose all financial relationships with any ineligible company. The ACCME defines “ineligible companies” as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products by or on patients. A relevant relationship exists if a financial relationship in any amount exists between the person in control of content and an ineligible company; the financial relationship existed during the past 24 months and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. MediCom will identify mitigation strategies for all persons with relevant financial relationships who control content of the educational activity.
Faculty Disclosures
Dr. Robert Sidonio, Jr. has relevant financial relationships related to consulting from Bayer AG, Genentech, Inc., Grifols S.A., Guardian Therapeutics, Novo Nordisk A/S, Octapharma USA, Inc., Sanofi, Sobi, and Takeda Oncology, as well as investigator sponsored studies from Genentech, Octapharma, and Takeda.
Dr. Miguel Escobar has relevant financial relationships related to advisory activities from CSL Behring, Genentech - A Member of the Roche Group, HEMA Biologics, LLC, LFB Biopharmaceuticals Limited, Novo Nordisk A/S, Pfizer Inc., Sanofi, Takeda Oncology, and uniQure N.V., as well as consulting from HEMA Biologics and LFB. He is on the speakers’ bureau for Bayer AG, BioMarin Pharmaceutical Inc., and Kedrion, and has received research grant(s) from Genentech - A Member of the Roche Group, Novo Nordisk A/S, Sanofi, Takeda, and uniQure.
Dr. Angela Weyand has relevant financial relationships related to consulting from Bayer AG, Genentech - A Member of the Roche Group, Sanofi, and Takeda Oncology. She has received research grant(s) from Novo Nordisk A/S, Pfizer Inc., Sanofi, and Takeda.
All of the relevant financial relationships listed for these individuals have been mitigated. |
Unapproved Product Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses of products or devices.
Planning Committee
Joan Meyer, RN, MHA, Executive Director, Isabelle Vacher, Vice President of Educational Strategy, and Andrea Mathis, Project Manager, planners for this educational activity, have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.
Peer Reviewer
Peer reviewer(s) for this educational activity have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.
Instructions for Participation and Credit
In order to participate in this activity, you must be registered to attend the 2022 Thrombosis & Hemostasis Summit of North America Conference. You can register by clicking here.
In order to receive credit, all participants must complete the post-test and activity evaluation following the activity. Partial credit will not be awarded for this activity. Participants must receive a minimum score of 70% on the self-assessment to qualify for CE credit.
Participants must complete the printed evaluation in order to claim credit for participation. Certificates will be emailed within 4 weeks to those who have successfully met the criteria for completion.
If you have any questions regarding this activity, please contact MediCom Worldwide, Inc. at 800-408-4242, x110 or [email protected]. |
| Provided by |
|
Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc. |
|
|
|
|
| ©2022 MediCom Worldwide, Inc., 660 Newtown Yardley Rd, Suite 203 · Newtown, PA 18940, 800-408-4242. No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc. |
|
